AbbVie’s Rinvoq (upadacitinib) Receives ANVISA’s Approval for Rheumatoid Arthritis

 AbbVie’s Rinvoq (upadacitinib) Receives ANVISA’s Approval for Rheumatoid Arthritis

AbbVie’s Rinvoq (upadacitinib) Receives ANVISA’s Approval for Rheumatoid Arthritis

Shots:

  • The approval is based on five P-III studies of SELECT program, assessing Rinvoq in ~4,400 patients, including in Brazil
  • The studies resulted in meeting its 1EPs & 2EPs. In SELECT COMPARE study, @12wks, 29% of patients receiving Rinvoq + MTX (methotrexate) achieved remission assessed by the DAS28 – PCR index
  • Rinvoq (PO, qd) is JAK inhibitor, indicated to treat active, moderate to severe RA, who did not respond adequately or who were intolerant to one or more DMARD

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post